Transfer of Material. The transfer of Material from one Party to the other Party will be governed by the terms and conditions of this Section 5.3, unless the Parties mutually agree otherwise. The Parties agree that the Pfizer Compound, and other compounds, materials, biological samples, and other physical property (altogether, the “Material”) of each Party may be provided to the other Party and used by the other Party solely for the purpose of the Project Plan and solely in the laboratories or clinics of that Party by personnel described in the Project Plan. Accordingly, any and all Material of a Party will be treated as Confidential Information of that Party in accordance with Article 7. Any transfer of Material or other physical property by one Party to the other Party’s site shall require the prior written consent of both Parties in the form of Exhibit C1 (for the transfer of Material not derived from human tissue) or Exhibit C2 (for the transfer of Material derived from human tissue). Detailed records of all such transferred items will be kept by AMC and Pfizer. All such Material shall be transferred to the other Party by secure means. All such Material shall remain the property of the transferring Party and will be surrendered to the transferring Party promptly or destroyed after the transferring Party provides to the other Party a written request for such return or destruction. No license, express or implied, is granted to the other Party in respect of such supplied Material other than as expressly stated in this Agreement. [this section should be modified accordingly if the research plan does not contemplate transfer of materials from AMC to Pfizer]
Appears in 2 contracts
Samples: Collaborative Research Agreement, Collaborative Research Agreement
Transfer of Material. The transfer of Material from one Party to the other Party will be governed by the terms and conditions of this Section 5.3, unless the Parties mutually agree otherwise. The Parties agree that the Pfizer COMPANY Compound, and other compounds, materials, biological samples, and other physical property (altogether, the “Material”) of each Party may be provided to the other Party and used by the other Party solely for the purpose of the Project Plan and solely in the laboratories or clinics of that Party by personnel described in the Project Plan. Accordingly, any and all Material of a Party will be treated as Confidential Information of that Party in accordance with Article 7. Any transfer of Material or other physical property by one Party to the other Party’s site shall require the prior written consent of both Parties in the form of Exhibit C1 (for the transfer of Material not derived from human tissue) or Exhibit C2 (for the transfer of Material derived from human tissue). Detailed records of all such transferred items will be kept by AMC and PfizerTHE COMPANY. All such Material shall be transferred to the other Party by secure means. All such Material shall remain the property of the transferring Party and will be surrendered to the transferring Party promptly or destroyed after the transferring Party provides to the other Party a written request for such return or destruction. AMC shall not conduct any research on Materials collected or created by using the COMPANY Compound (e.g., blood, plasma, cell extracts, tissue samples from animals or humans) other than that set forth in the Program or Clinical Trial Agreement. No license, express or implied, is granted to the other Party in respect of such supplied Material other than as expressly stated in this Agreement. [this section should be modified accordingly if the research plan does not contemplate transfer of materials from AMC to Pfizer].
Appears in 1 contract
Samples: Collaborative Research Agreement
Transfer of Material. The transfer of Material from one Party to the other Party will be governed by the terms and conditions of this Section 5.35.4, unless the Parties mutually agree otherwise. The Parties agree that the Pfizer AstraZeneca Compound, and other compounds, materials, biological samples, and other physical property (altogether, the “Material”) of each Party may be provided to the other Party and used by the other Party solely for the purpose of the Project Plan and solely in the laboratories or clinics of that Party by personnel described in the Project Plan. Accordingly, any and all Material of a Party will be treated as Confidential Information of that Party in accordance with Article 7. Any Except for transfer of AstraZeneca Compound under the ESCR Agreement in Exhibit B, any transfer of Material or other physical property by one Party to the other Party’s site shall require the prior written consent of both Parties in the form of Exhibit C1 (for the transfer of Material not derived from human tissue) or Exhibit C2 (for the transfer of Material derived from human tissue). Detailed records of all such transferred items will be kept by AMC and PfizerAstraZeneca. All such Material shall be transferred to the other Party by secure means. All such Material shall remain the property of the transferring Party and will be surrendered to the transferring Party promptly or destroyed after the transferring Party provides to the other Party a written request for such return or destruction. No license, express or implied, is granted to the other Party in respect of such supplied Material other than as expressly stated in this Agreement. [this section should be modified accordingly if the research plan does not contemplate transfer of materials from AMC to Pfizer].
Appears in 1 contract
Samples: Collaborative Research Agreement
Transfer of Material. The transfer of Material from one Party to the other Party will be governed by the terms and conditions of this Section 5.3, unless the Parties mutually agree otherwise. The Parties agree that the Pfizer Company Compound, and other compounds, materials, biological samples, and other physical property (altogether, the “Material”) of each Party may be provided to the other Party and used by the other Party solely for the purpose of the Project Plan and solely in the laboratories or clinics of that Party by personnel described in the Project Plan. Accordingly, any and all Material of a Party will be treated as Confidential Information of that Party in accordance with Article 7. Any transfer of Material or other physical property by one Party to the other Party’s site shall require the prior written consent of both Parties in the form of Exhibit C1 B1 (for the transfer of Material not derived from human tissue) or Exhibit C2 B2 (for the transfer of Material derived from human tissue). Detailed records of all such transferred items will be kept by AMC and PfizerCompany. All such Material shall be transferred to the other Party by secure means. All such Material shall remain the property of the transferring Party and will be surrendered to the transferring Party promptly or destroyed after the transferring Party provides to the other Party a written request for such return or destruction. No license, express or implied, is granted to the other Party in respect of such supplied Material other than as expressly stated in this Agreement. [this section should be modified accordingly if the research plan does not contemplate transfer of materials from AMC to Pfizer].
Appears in 1 contract
Samples: Collaborative Research Agreement
Transfer of Material. The transfer of Material from one Party to the other Party will be governed by the terms and conditions of this Section 5.3, unless the Parties mutually agree otherwise. The Parties agree that the Pfizer Compound, and other compounds, materials, biological samples, and other physical property (altogether, the “Material”) of each Party may be provided to the other Party and used by the other Party solely for the purpose of the Project Plan and solely in the laboratories or clinics of that Party by personnel described in the Project Plan. Accordingly, any and all Material of a Party will be treated as Confidential Information of that Party in accordance with Article 7. Any transfer of Material or other physical property by one Party to the other Party’s site shall require the prior written consent of both Parties in the form of Exhibit C1 (for the transfer of Material not derived from human tissue) or Exhibit C2 (for the transfer of Material derived from human tissue). Detailed records of all such transferred items will be kept by AMC and Pfizer. All such Material shall be transferred to the other Party by secure means. All such Material shall remain the property of the transferring Party and will be surrendered to the transferring Party promptly or destroyed after the transferring Party provides to the other Party a written request for such return or destruction. No license, express or implied, is granted to the other Party in respect of such supplied Material other than as expressly stated in this Agreement. [this section should be modified accordingly if the research plan does not contemplate transfer of materials from AMC to Pfizer]Agreement.
Appears in 1 contract
Samples: Collaborative Research Agreement